181 related articles for article (PubMed ID: 31974273)
1. Macrophage Syk-PI3Kγ Inhibits Antitumor Immunity: SRX3207, a Novel Dual Syk-PI3K Inhibitory Chemotype Relieves Tumor Immunosuppression.
Joshi S; Liu KX; Zulcic M; Singh AR; Skola D; Glass CK; Sanders PD; Sharabi AB; Pham TV; Tamayo P; Shiang D; Dinh HQ; Hedrick CC; Morales GA; Garlich JR; Durden DL
Mol Cancer Ther; 2020 Mar; 19(3):755-764. PubMed ID: 31974273
[TBL] [Abstract][Full Text] [Related]
2. PI3Kγ is a molecular switch that controls immune suppression.
Kaneda MM; Messer KS; Ralainirina N; Li H; Leem CJ; Gorjestani S; Woo G; Nguyen AV; Figueiredo CC; Foubert P; Schmid MC; Pink M; Winkler DG; Rausch M; Palombella VJ; Kutok J; McGovern K; Frazer KA; Wu X; Karin M; Sasik R; Cohen EE; Varner JA
Nature; 2016 Nov; 539(7629):437-442. PubMed ID: 27642729
[TBL] [Abstract][Full Text] [Related]
3. SF2523: Dual PI3K/BRD4 Inhibitor Blocks Tumor Immunosuppression and Promotes Adaptive Immune Responses in Cancer.
Joshi S; Singh AR; Liu KX; Pham TV; Zulcic M; Skola D; Chun HB; Glass CK; Morales GA; Garlich JR; Durden DL
Mol Cancer Ther; 2019 Jun; 18(6):1036-1044. PubMed ID: 31018997
[TBL] [Abstract][Full Text] [Related]
4. Macrophage PI3Kγ Drives Pancreatic Ductal Adenocarcinoma Progression.
Kaneda MM; Cappello P; Nguyen AV; Ralainirina N; Hardamon CR; Foubert P; Schmid MC; Sun P; Mose E; Bouvet M; Lowy AM; Valasek MA; Sasik R; Novelli F; Hirsch E; Varner JA
Cancer Discov; 2016 Aug; 6(8):870-85. PubMed ID: 27179037
[TBL] [Abstract][Full Text] [Related]
5. PI3K Inhibition Reduces Mammary Tumor Growth and Facilitates Antitumor Immunity and Anti-PD1 Responses.
Sai J; Owens P; Novitskiy SV; Hawkins OE; Vilgelm AE; Yang J; Sobolik T; Lavender N; Johnson AC; McClain C; Ayers GD; Kelley MC; Sanders M; Mayer IA; Moses HL; Boothby M; Richmond A
Clin Cancer Res; 2017 Jul; 23(13):3371-3384. PubMed ID: 28003307
[No Abstract] [Full Text] [Related]
6. Immunotherapy with PI3K inhibitor and Toll-like receptor agonist induces IFN-γ+IL-17+ polyfunctional T cells that mediate rejection of murine tumors.
Marshall NA; Galvin KC; Corcoran AM; Boon L; Higgs R; Mills KH
Cancer Res; 2012 Feb; 72(3):581-91. PubMed ID: 22158905
[TBL] [Abstract][Full Text] [Related]
7. A Dual PI3K/HDAC Inhibitor Induces Immunogenic Ferroptosis to Potentiate Cancer Immune Checkpoint Therapy.
Fan F; Liu P; Bao R; Chen J; Zhou M; Mo Z; Ma Y; Liu H; Zhou Y; Cai X; Qian C; Liu X
Cancer Res; 2021 Dec; 81(24):6233-6245. PubMed ID: 34711611
[TBL] [Abstract][Full Text] [Related]
8. Immuno-oncology agent IPI-549 is a modulator of P-glycoprotein (P-gp, MDR1, ABCB1)-mediated multidrug resistance (MDR) in cancer: In vitro and in vivo.
De Vera AA; Gupta P; Lei Z; Liao D; Narayanan S; Teng Q; Reznik SE; Chen ZS
Cancer Lett; 2019 Feb; 442():91-103. PubMed ID: 30391357
[TBL] [Abstract][Full Text] [Related]
9. The Mincle/Syk/NF-κB Signaling Circuit Is Essential for Maintaining the Protumoral Activities of Tumor-Associated Macrophages.
Li C; Xue VW; Wang QM; Lian GY; Huang XR; Lee TL; To KF; Tang PM; Lan HY
Cancer Immunol Res; 2020 Aug; 8(8):1004-1017. PubMed ID: 32532809
[TBL] [Abstract][Full Text] [Related]
10. The FBW7-MCL-1 axis is key in M1 and M2 macrophage-related colon cancer cell progression: validating the immunotherapeutic value of targeting PI3Kγ.
Lee YS; Song SJ; Hong HK; Oh BY; Lee WY; Cho YB
Exp Mol Med; 2020 May; 52(5):815-831. PubMed ID: 32444799
[TBL] [Abstract][Full Text] [Related]
11. Immuno-oncological Efficacy of RXDX-106, a Novel TAM (TYRO3, AXL, MER) Family Small-Molecule Kinase Inhibitor.
Yokoyama Y; Lew ED; Seelige R; Tindall EA; Walsh C; Fagan PC; Lee JY; Nevarez R; Oh J; Tucker KD; Chen M; Diliberto A; Vaaler H; Smith KM; Albert A; Li G; Bui JD
Cancer Res; 2019 Apr; 79(8):1996-2008. PubMed ID: 30723115
[TBL] [Abstract][Full Text] [Related]
12. Shp1 Loss Enhances Macrophage Effector Function and Promotes Anti-Tumor Immunity.
Myers DR; Abram CL; Wildes D; Belwafa A; Welsh AMN; Schulze CJ; Choy TJ; Nguyen T; Omaque N; Hu Y; Singh M; Hansen R; Goldsmith MA; Quintana E; Smith JAM; Lowell CA
Front Immunol; 2020; 11():576310. PubMed ID: 33133093
[TBL] [Abstract][Full Text] [Related]
13. TREM-2 serves as a negative immune regulator through Syk pathway in an IL-10 dependent manner in lung cancer.
Yao Y; Li H; Chen J; Xu W; Yang G; Bao Z; Xia D; Lu G; Hu S; Zhou J
Oncotarget; 2016 May; 7(20):29620-34. PubMed ID: 27102437
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Rspo-Lgr4 Facilitates Checkpoint Blockade Therapy by Switching Macrophage Polarization.
Tan B; Shi X; Zhang J; Qin J; Zhang N; Ren H; Qian M; Siwko S; Carmon K; Liu Q; Han H; Du B; Liu M
Cancer Res; 2018 Sep; 78(17):4929-4942. PubMed ID: 29967265
[TBL] [Abstract][Full Text] [Related]
15. Syk Inhibition Reprograms Tumor-Associated Macrophages and Overcomes Gemcitabine-Induced Immunosuppression in Pancreatic Ductal Adenocarcinoma.
Rohila D; Park IH; Pham TV; Weitz J; Hurtado de Mendoza T; Madheswaran S; Ishfaq M; Beaman C; Tapia E; Sun S; Patel J; Tamayo P; Lowy AM; Joshi S
Cancer Res; 2023 Aug; 83(16):2675-2689. PubMed ID: 37306759
[TBL] [Abstract][Full Text] [Related]
16. PI3Kγ inhibition suppresses microglia/TAM accumulation in glioblastoma microenvironment to promote exceptional temozolomide response.
Li J; Kaneda MM; Ma J; Li M; Shepard RM; Patel K; Koga T; Sarver A; Furnari F; Xu B; Dhawan S; Ning J; Zhu H; Wu A; You G; Jiang T; Venteicher AS; Rich JN; Glass CK; Varner JA; Chen CC
Proc Natl Acad Sci U S A; 2021 Apr; 118(16):. PubMed ID: 33846242
[TBL] [Abstract][Full Text] [Related]
17. C-Type Lectin-Like Receptor 2 Suppresses AKT Signaling and Invasive Activities of Gastric Cancer Cells by Blocking Expression of Phosphoinositide 3-Kinase Subunits.
Wang L; Yin J; Wang X; Shao M; Duan F; Wu W; Peng P; Jin J; Tang Y; Ruan Y; Sun Y; Gu J
Gastroenterology; 2016 May; 150(5):1183-1195.e16. PubMed ID: 26855187
[TBL] [Abstract][Full Text] [Related]
18. Targeting macrophage Syk enhances responses to immune checkpoint blockade and radiotherapy in high-risk neuroblastoma.
Rohila D; Park IH; Pham TV; Jones R; Tapia E; Liu KX; Tamayo P; Yu A; Sharabi AB; Joshi S
Front Immunol; 2023; 14():1148317. PubMed ID: 37350973
[TBL] [Abstract][Full Text] [Related]
19. PI3Kγ Activates Integrin α
Foubert P; Kaneda MM; Varner JA
Cancer Immunol Res; 2017 Nov; 5(11):957-968. PubMed ID: 28963139
[TBL] [Abstract][Full Text] [Related]
20. Syk-MyD88 Axis Is a Critical Determinant of Inflammatory-Response in Activated Macrophages.
Yi YS; Kim HG; Kim JH; Yang WS; Kim E; Jeong D; Park JG; Aziz N; Kim S; Parameswaran N; Cho JY
Front Immunol; 2021; 12():767366. PubMed ID: 35003083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
